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Summary 
CD4 T helper precursor cells mature along two alterna- 
tive pathways, Thl and Th2. Here we show that these 
pathways are differentially activated by two costimula- 
tory molecules, B7-1 and B7-2. Using anti-B7 antibod- 
ies, this developmental step was manipulated both in 
vitro and in vivo in experimental allergic encephalomy- 
elitis (EAE). Anti-B7-1 reduced the incidence of dis- 
ease while anti-B7-2 increased disease severity. Nei- 
ther antibody affected overall T cell induction but 
rather altered cytokine profile. Administration of anti- 
B7-1 at immunization resulted in predominant genera- 
tion of Th2 clones whose transfer both prevented in- 
duction of EAE and abrogated established disease. 
Since cotreatment with anti-lL-4 antibody prevented 
disease amelioration, costim ulatory molecules may di- 
rectly affect initial cytokine secretion. Thus, interac- 
tion of B7-1 and B7-2 with shared counterreceptors 
CD28 and CTLA-4 results in very different outcomes 
in clinical disease by influencing commitment of pre- 
cursors to a Thl or Th2 lineage. 
Introduction 
CD4 ÷ T helper (Th) cells, upon antigenic stimulation, differ- 
entiate into two distinct subpopulations, each producing 
its own set of cytokines and mediating separate effector 
functions (Mosmann and Coffman, 1989; Seder and Paul, 
1994). Type 1 Th cells (Thl) produce interleukin-2 (IL-2), 
tThe first wo authors contributed equally to this work. 
tumor necrosis factor 13 (TNFI3), and interferon-7 (IFNT), 
thereby activating macrophages and inducing delayed- 
type hypersensitivity responses. Type 2 Th cells (Th2) pro- 
duce IL-4, IL-5, and IL-10, stimulating production of mast 
cells, eosinophils, and immunoglobulin G1 (IgG1) and IgE 
antibodies and possibly suppressing cell-mediated immu- 
nity (Powrie and Coffman, 1993; Mosmann and Coffman, 
1989). Because their respective cytokines act antagonisti- 
cally, these two cell populations mutually regulate the 
function of the other (Seder and Paul, 1994). 
The differentiation of Th precursor (Thp) cells into Thl 
or Th2 cells has important biologic implications in terms 
of susceptibility or resistance to a particular disease. In 
Leishmania major parasitic infections, there is reciprocal 
expression of IFN~, and IL-4 in mice of different back- 
grounds that correlates with resolution or progression of 
disease (Heinzel et al., 1989). Further, human immunode- 
ficiency virus-infected individuals switch from a Thl to a 
Th2 phenotype as symptoms worsen (Cohen, 1993), while 
patients with rheumatoid arthritis have predominantly Th 1 
cells in synovial tissue (Simon et al., 1994). Several organ- 
specific autoimmune diseases, including experimental l- 
lergic encephalomyelitis (EAE), are induced by autoreac- 
rive Thl cells (Kuchroo et al., 1993; Baron et al., 1993). 
Furthermore, regulatory T cells that suppress the develop- 
ment of EAE produce Th2 cytokines (Chen et al., 1994), 
and recovery from EAE in mice and rats is associated 
with an increase in Th2 cells and cytokines in the central 
nervous system (CNS) (Khoury et al., 1992). These find- 
ings, along with the observation that Th2 cytokines can 
inhibit the actions of the inflammatory Thl cytokines, sug- 
gest that the modalities that induce and activate Th2 cells 
and cytokines may prevent EAE and other autoimmune 
diseases mediated by Thl cells. 
In spite of the importance of Th lineage commitment in 
disease, mechanisms that determine whether an immune 
response will be dominated by Thl or Th2 cells are not 
well understood (Seder and Paul, 1994). The dominant 
factors that control the differentiation of Thl and Th2 cells 
from Thp cells may be cytokines. Thus, IFN'y and IL-4 
reciprocally autoregulate the differentiation of Thp into ma- 
ture Thl and Th2 effector cells; IFN7 enhances Thl while 
inhibiting Th2 development, while IL-4 has the opposite 
effect. However, the initial T cell signaling events that de- 
termine whether Thp cells produce IL-4 or IFN7 and thus 
initiate Thl versus Th2 differentiation are unknown, al- 
though secretion of IL-12 from macrophages and IL-4 from 
CD4 + NK-like cells may be important (Trinchieri, 1993; 
Yoshimoto and Paul, 1994). 
Induction and activation of T lymphocytes require two 
signals from antigen-presenting cells (APCs). The first sig- 
nal, the binding of the T cell receptor (TCR) to its antigen- 
major histocompatibility complex (MHC) ligand, provides 
specificity. The second signal is provided by costimulatory 
molecules expressed on APCs. Of the known costimula- 
tory molecules, the family of proteins termed B7 appears 
to be the most potent. The B7 costimulatory pathway in- 
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volves at least two molecules, B7-1 (CD80) (Freeman et 
al., 1991) and B7-2 (CD86) (Azuma et al., 1993; Freeman 
et al., 1993a, 1993b), both of which can interact with their 
counterreceptors, CD28 and CTLA-4, on T cells (Linsley 
et al., 1991; Freeman et al., 1993a, 1993b). Blocking B7-1 
interactions during T cell activation induces functional in- 
activation in Thl cells, leading to a state of hyporespon- 
siveness or anergy (Schwartz, 1992; Chen and Nabavi, 
1994), and B7-1 knockout mice have significantly reduced 
immune responses (Freeman et al., 1993a). Although B7-2 
is predicted to have a function similar to that of B7-1, the 
difference in the temporal expression of these two costim- 
ulatory molecules on T cells and APCs (Nabavi et al., 1992; 
Chen et al., 1994; Hathcock et al., 1994) suggests that 
these molecules may have different functions. 
In this report we describe the role of B7 costimulatory 
molecules (B7-1 and B7-2) in the development of Thl and 
Th2 cells from Thp cells. Using an in vitro T cell differentia- 
tion assay of T cells from a myelin basic protein (MBP) 
transgenic mouse, we show that anti-B7-1 increases the 
production of IL-4, whereas anti-B7-2 enhances the pro- 
duction of IFNy. Furthermore, the majority of Th clones 
derived from anti-B7-1-injected mice were of the Th2 phe- 
notype. This information was used to manipulate the two 
subsets selectively in vivo to affect the induction of the 
autoimmune disease EAE. Administration of anti-B7-1 anti- 
body significantly reduced the incidence of EAE, an effect 
prevented by simultaneous administration of anti-lL-4 
monoclonal antibody (MAb), whereas injection of anti-B7-2 
antibody substantially increased disease severity. Injec- 
tion of anti-B7 antibody did not significantly affect the in- 
duction of T cells to the immunizing antigen, but rather 
altered the cytokine profile of the responding T cells. In- 
deed, transfer of proteolipid protein (PLP)-specific Th2 
clones prevented induction of EAE and abrogated estab- 
lished disease. These data suggest that treatment with 
anti-B7 antibodies can alter the course of autoimmune 
disease by differentially influencing the development of 
mature Thl and Th2 effector cells from uncommitted Thp 
cells and raise therapeutic options for the immunoselec- 
tive treatment of human organ-specific autoimmunity. 
Results 
Anti-B7-1 and Anti-B7-2 Antibodies Differentially 
Affect T Cell Development In Vitro 
To test whether B7-1 and B7-2 molecules may affect the 
generation of Th 1 versus Th2 cells/cytokines in peripheral 
lymphoid tissue, we studied the differentiation of naive T 
cells from two separate MBP TCR transgenic mouse lines 
in the presence of anti-B7-1 or anti-B7-2 antibodies in vitro 
(Lafaille et al., 1994; Goverma.n et al., 1993). That these 
resting MBP TCR transgenic T cells were indeed naive or 
precursor cells was suggested by their phenotype of lower 
level expression of two T cell markers, CD44 (pgp-1) and 
IL-2 receptor (CD25), more characteristic of mature/mem- 
ory T cells than TCR transgenic T cells from MBP-activated 
cultures (data not shown). Spleen cells from a separate 
MBP-specific TCR transgenic mouse line (Goverman et 












I000 B7-2 " ,:~-~!~;'~'~;i: 
 oo_ 
~°°' I ~ ?~! 
200 ~ ?~i:;; 










Figure 1. Effect of Anti-B7 Antibodies on In Vitro Differentiation f Th 
Ceils 
Spleen cells from a naive MBP-specific TCR transgenic mouse were 
activated with MBP Ac(1-11) and various anti-B7 antibodies or with 
control rat immunoglobulin. After 21 days of resting, the T cells from 
each culture were purified and then reactivated with antigen and syn- 
geneic APCs in the presence of the respective anti-B7 or control anti- 
bodies• The amount of cytokine produced by each culture after 48 hr 
of activation with MBP Ac(1-11) or control peptide PLP(139-151) was 
determined by ELISA. 
and activated in the presence of MBP Ac(1-11) peptide 
with the addition of anti-B7 or control reagents. Cells were 
then rested for 21 days in vitro, harvested, and activated 
again in the presence of antigen and anti-B7 antibodies 
(secondary stimulation), and cytokine production was de- 
termined. The data presented in Figure 1 show quantita- 
tive differences in IFN~ and IL-4 production but not in IL-2 
and IL-10 production in culture supernatants following sec- 
ondary stimulation, but not after primary stimulation that 
produced only Thl cytokines (data not shown). A dramatic 
increase in IFN~, production in cultures treated with anti- 
B7-2 antibody (11.7 ng/ml) was observed when compared 
with phosphate-buffered saline (PBS) (5.5 ng/ml) or rat 
immunoglobulin (3.8 ng/ml) controls. The amount of IFN~, 
produced in the presence of anti-B7-1 was similar to that 
seen in the control cultures. Conversely, T cell lines de- 
rived in the presence of anti-B7-1 produced 4- to 5-fold 
more IL-4 than T cells from cultures treated with PBS or 
anti-B7-2. There was a small increase in IL-4 production 
in the presence of rat immunoglobulin, but this was sig- 
nificantly lower than with anti-B7-1. The data can be 
expressed in terms of ratios of Thl to Th2 cytokines in 
B7-1- versus B7-2-treated cultures, Thus, IFN~ ratios are 
B7-1/B7-2 of 0.34 while IL-4 ratios are B7-1/B7-2 of 3.6. 
This results in a skewing of Thl/Th2 cytokines of 10.6-fold. 
There was no significant decrease in IFN~, production in 
cultures treated with anti-B7-1 antibody despite an in- 
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Figure 2. EffectoflnjectionofAnti-B7andControlAntibodiesonClini- 
cal EAE 
(A) Groups of ten animals each were immunized with PLP(139-151) 
peptide in CFA (50 ~.g/mouse) and injected intraperitoneally with 100 
~g/mouse of anti-B7 antibodies (anti-B7-1 or anti-B7-2), with a mixture 
of both anti-B7 antibodies, or with PBS every other day. The treatment 
was stopped at day 20, as indicated by the arrow. The data are pre- 
sented as the mean disease score in each group on different days of 
observation. 
(B and C) Groups of 5-15 mice were immunized with PLP(139-151) 
in CFA (25 ~g/mouse) and injected intraperitoneally every other day 
for 30 days with 100 p~g/mouse of anti-B7 antibodies or isotype- 
matched rat antibody as control. The data are presented as mean 
disease scores in each group on different days of observation. 
crease in IL-4 production. It is possible that the T cells from 
the MBP TCR transgenic mice that have differentiated to 
Thl cells in vivo do not revert and continue to produce 
IFN~, in vitro following antigen-specific stimulation. Indeed, 
in an experiment (data not shown) in which we failed to 
drive Th differentiation with anti-B7 antibodies, concurrent 
fluorescence-activated cell sorting analysis of resting cells 
showed extremely high levels of CD44 and IL-2 receptor 
expression, as well as high levels of IFN7 secretion, sug- 
gesting that these T cells were no longer Thp cells and, 
thus, could not be further differentiated. In the experiment 
in Figure 1, there were no significant differences in IL-10 
production in various treatment groups, suggesting that 
it may be regulated ifferently from IL-4. However, in addi- 
tional experiments using cells from three separate TCR 
transgenic lines, a substantial Th 1/-I-h2 shift was achieved 
by the dramatic effect of anti-B7-2 in decreasing or abro- 
gating production of IL-4, IL-10, or both. IL-2 also de- 
creased in two of the three experiments with anti-B7-2. 
In these experiments, anti-B7-1 did not increase IL-4 or 
decrease IFN7 production (A. M. R. and L. H. G., unpub- 
lished data). Overall, these data demonstrate that antigen- 
specific activation of T cells in the presence of either anti- 
B7-1 or B7-2 results in the polarization of Th cells to T 
cells that predominantly produce Thl or Th2 cytokines. 
MAbs to Costimulatory Molecules B7-1 and B7-2 
Have Opposite Effects on the Development 
of EAE 
We then used this information to manipulate Th cell differ- 
entiation in vivo in EAE. To test the effect of anti-B7 anti- 
bodies on the development of EAE, we immunized SJL 
mice with various amounts of peptide PLP(139-151) in 
complete Freund's adjuvant (CFA). The mice were also 
injected with anti-B7-1, anti-B7-2, or control antibodies. In 
the first series Of experiments, SJL mice were immunized 
with 50 p.g of PLP(139-151) in CFA and injected every 
other day with 100 i,g/mouse of anti-B7-1, anti-B7-2, a 
mixture of anti-B7-1 plus anti-B7-2, or PBS. The antibody 
treatment was continued up to day 20. The data in Figure 
2A give the mean disease scores of each group over a 
period of 1 month. In the PBS-injected control group, mice 
started showing signs of EAE on day 12 with peak disease 
(mean disease score of 2.4) on day 15. By days 17 and 
18, disease began to remit, and the majority of the mice in 
this group were free of disease by day 20. In the anti-B7-1 
(1G10)-treated group, there was a delay in the onset of 
disease with peak disease (mean score of 1) on day 19; 
by day 20 mice that were sick began to remit. Interestingly, 
at day 20, when the antibody treatment was halted, mice 
that had not previously shown signs of disease became 
symptomatic, and a second peak of disease (mean dis- 
ease score of 1.5) appeared on day 24. Treatment with 
anti-B7-2 (2D10) alone did not have any ameliorating effect 
on disease. Similarly, treatment with a mixture of anti-B7-1 
and anti-B7-2 had only a slight effect on delaying disease 
onset, and disease peaked on day 18 after immunization. 
The results from this initial experiment suggested that in- 
jection of anti-B7-1 alone had the most effect in ameliorat- 
ing disease. The data further suggested that this was di- 
rectly related to the antibody treatment, since stopping 
treatment on day 20 resulted in the appearance of disease 
in the remainder of the animals. 
Accordingly, in the next experiment, the antigen dose 
was reduced (25 i,g/mouse of PLP peptide in CFA) to in- 
duce milder disease, and mice were injected intraperitone- 
ally with 100 ~g/mouse of anti-B7 or control antibodies 
every other day for the entire length of the experiment. 
The data (Table 1; Figures 2B and 2C) demonstrate that, 
when compared with PBS or control antibody (TR-310), 
administration of anti-B7-1 antibody significantly inhibited 
EAE induction. A significant decrease in the incidence of 
disease (43% as compared with 100% in PBS controls) 
was observed, but there was no difference in the day of 
onset or the severity of disease in those mice that did 
develop EAE (experiment 1 in Table 1). Conversely, the 
same dose of two different anti-B7-2 antibodies (2D10 and 
GL-1) significantly increased disease severity. Isotype- 
matched antibody controls (rat IgG2a and lgG2b) did not 
significantly alter disease course or severity (experiments 
1 and 2 in Table 1) when compared with PBS. The course 
of disease shown as cumulative clinical disease scores 
in different groups of mice on each day over the course 
Cell 
710 
Table 1. Effect of Anti-B7-1 and Anti-B7-2 Antibody Treatment on EAE 
Histological Lesions 
Clinical Disease Number of Foci in Mice 
TreatmenP Incidence Day of Onset Severity b Incidence With Disease Without Disease 
First Experiment 
PBS 13 of 13 14.2 _ 0.7 2.8 - 0.2 13 of 13 61.9 -*- 16.2 NA 
TR-310 14 of 15 13.2 +_ 1.1 2.8 _ 0.3 15 of 15 52.8 __. 10.5 NA 
Anti-B7-1 (1G10) 6 of 1~4 c 14.5 _ 1.0 2.7 _ 0.6 12 of 14 64.4 ± 22.9 7.8 
Anti-BT-2 (2D10) 9 of 9 12.6 __. 0.3 4.7 - 0.1 ¢ 6 of 6 95.0 ± 10.4 NA 
Second experiment 
PBS 5 of 6 13.8 ± 0.6 3.1 ± 0.5 ND ND ND 
IgG2a 5 of 5 . 13.8 ± 0.2 3.5 __- 0.4 ND ND ND 
IgG2b 5 of 6 13.0 - 0.0 3.2 ± 0.7 ND ND ND 
Anti-B7-2 (2D10) 5 of 5 13.0 ± 0.0 5.0 ± 0.0 ~ ND ND ND 
Anti-BT-2 (GL-1) 4 of 5 13.5 _+ 0.3 4.5 ± 0.3 ° ND ND ND 
± 2.2 
Abbreviations: ND, not determined; NA, not applicable. 
"Animals were immunized with PLP(139-151) in CFA and injected intraperitoneally with 100 ~.g/mouse ofvarious antibodies or PBS. 
b Data are presented as mean clinical scores for the animals howing clinical disease. 
° Statistically significant; P < 0.001. 
of an entire month is shown in Figures 2B and 2C. In an 
additional experiment, animals immunized with a larger 
dose of antigen (100 i~g/mouse of PLP[139-151] in CFA) 
and injected with anti-B7-1 or anti-B7-2 antibodies devel- 
oped a severe EAE that could not be suppressed by the 
anti-B7 antibody treatment. 
Histopathological nalysis of the brains and spinal cords 
of the mice was also performed. In general, there was a 
close correlation between clinical scores and the number 
of inflammatory foci in brain and spinal cords (experiment 
1 in Table 1). In particular, 1G10-treated mice that did not 
develop EAE had few or no lesions while those that did 
develop disease had significantly fewer lesions than 2D 10- 
treated and control-treated (PBS or TR-310 antibody) mice 
(Figure 3). 
Cytokine-specific polymerase chain reaction (PCR) from 
brain-derived cDNA revealed a uniform distribution of Th 1- 
and Th2-specific cytokines in all mice with the exception 
of one disease-free animal from the 1G10 group, which 
expressed IL-4 but negligible amounts of other cytokines 
by PCR, consistent with the presence of Th2 cells (data not 
shown). Careful quantitative determinations of cytokine 
levels at multiple timepoints over the course of disease 
progression would be required to detect differences in 
Thl/ 'rh2 ratios in control versus anti-B7-treated animals. 
Anti-B7 Antibodies Do Not Inhibit the Induction 
of T Cells In Vivo but Influence 
Cytokine Profile 
To study the immunological basis for the opposing effects 
of anti-B7 antibodies on disease induction, we tested for 
specific proliferative responses and production of various 
cytokines (IL-2, IFNy, IL-4, and IL-10) following in vitro stim- 
ulation with PLP using lymph node cells (LNCs) from mice 
immunized with peptide PLP(139-151) and treated with 
anti-B7 or control antibodies. The LNCs from each group 
showed significant proliferative responses to the immuniz- 
ing antigen and not to the control peptide PLP(190-209) 
(data not shown). The data, presented as stimulation indi- 
ces for each group (Figure 4A), showed mean stimulation 
indices of 10.8 _ 3.4, 12.1 -4- 3.5, 8.4 _+ 1.8, and 10.4 _+ 
2.9, respectively, for the PBS-treated, TR-310-treated, 
anti-B7-1-treated, and anti-B7-2-treated groups. 
LNCs from PLP-immunized and antibody-treated mice 
were also cultured with media alone, with immunizing pep- 
tide PLP(139-151), or with control peptide P LP(190-209). 
Culture supernatants were harvested 24 and 48 hr later, 
and the amount of cytokine present was measured by 
cytokine-specific enzyme-linked immunosorbent assay 
(ELISA). Data presented in Figure 4B show no differ- 
ence in IL-2 production in PBS-treated (470 _+ 170 pg/ml), 
TR-310-treated (535 _ 230 pg/ml), or anti-B7-1-treated 
(491 _ 180 pg/ml) groups. There was a slight but not 
significant increase in IL-2 production (1045 --. 460)in the 
anti-B7-2-treated group. The amount of IFN'y in the same 
supernatants, however, varied widely among individual 
animals. Animals injected with PBS and control antibody 
TR-310 produced, on average, similar amounts of IFN~, 
(PBS at 1750 __. 730 versus TR-310 at 1770 _ 490 pg/ml; 
Figure 4C). Animals injected with anti-B7-1 (1G10) gener- 
ally produced little or no IFNy. However, LNCs from 1G10- 
treated mice that did develop EAE produced large quanti- 
ties of IFN,/following antigen activation (up to about 8200 
pg/ml), similar to that seen in the control groups. The mean 
IFN7 production in the anti-B7-1-treated group was about 
half (850 _ 540 pg/ml) that seen in the control groups. 
In contrast, LNCs from anti-B7-2-treated mice generally 
showed substantially increased production of IFN'y: the 
mean IFN~ (4860 ± 1240 pg/ml) production in this group 
was approximately 3- to 4-fold higher than control groups. 
No detectable levels of I L-4 or I L-10 were observed, consis- 
tent with previous difficulties in detecting Th2 cytokines 
in bulk lymph node cultures (Kuchroo et al., 1993; data 
not shown). In a separate experiment, we determined by 
depletion that the cytokines measured were being pro- 
duced by CD4 ÷ T cells and not by CD8 ÷ or NK cells in the 
culture (data not shown). 
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Figure 3. Histology 
(A) Anti-B7-2-treated SJL mouse with severe FAE. Prominent menin- 
geal and perivascular parenchymal mononuclear cell infiltrates are 
present in the spinal cord. Stained with Luxol fast blue-hematoxylin 
and eosin. Magnification, 83.8x. 
(B) Meningeal and perivascular inflammatory infiltrate in the spinal 
cord of an anti-TR-310 control MAb-treated mouse with severe EAE. 
Stained with Luxol fast blue-hematoxylin and eosin. Magnification, 
126.1 x.  
(C) Spinal cord white matter (central portion) and gray matter of an 
SJL mouse sensitized for EAE but treated with anti-B7-1 antibody. 
No inflammatory infiltrates are present. Stained with Luxol fast blue- 
hematoxylin and eosin. Magnification, 83.8 x.  
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Figure 4. Proliferation and Cytokine Production by the LNCs of Mice 
Immunized with PLP(139-151) and Injected with Anti-B7 Antibodies 
Groups of SJL mice were immunized with PLP(139-151) and injected 
with 100 I~g/mouse of anti-B7-1 or anti-B7-2, TR-310 (isotype control), 
or PBS. Lymph nodes were harvested at different times during the 
course of the experiment or on day 10 after immunization. The LNCs 
were then activated in triplicate wells with 100 i~g/ml PLP(139-151) 
or a control antigen. Proliferation (A) was measured in a 72 hr activation 
assay, and 1 p.Ci of [3H]thymidine was added during the last 16 hr of 
culture. The data were calculated as mean radioactivity incorporated 
in triplicate wells, The data have been presented as a stimulation index: 
mean counts per minute in test wells divided by mean counts per 
minute in wells with media. Levels of specific cytokines (IL-2 [B] and 
IFN~, [C]) were determined in 48 hr culture supernatant of the LNCs 
following antigen-specific activation. Means and standard errors of 
each group are shown. 
AnU-B7-1 Treatment In Viva Induces 
IL-4-Producing Th2 Cells 
The data suggested that anti-B7-1 did not mediate its ef- 
fects by inhibiting the overall generation of T cells. Since 
there was a reduction in the production of IFNy in the bulk 
cultures, we hypothesized that anti-BT-1 may ameliorate 
disease by either directly reducing the number of IFN~,- 
producing cells or, alternatively, by promoting the genera- 
tion of Th2 cells that may in turn inhibit IFN7 production. 
To address this issue, we initially plated purified lymph 
node T cells from the PLP(139-151)-immunized antibody- 
or control-treated mice, at 104 and 105 cells/ml (100 i~1/ 
well). The number of wells producing IFN'y and IL-4 was 
determined after estimulation with specific antigen in 
each treatment group. Interestingly, PBS-, TR-310-, and 
anti-B7-2-treated groups had approximately the same fre- 
quency of IL-4-producing cells (1 x 108 to 2 x 108 T cells) 
while there were five times more wells (5 x 106 to 6 x 106 
cells) that produced IL-4 following in viva administration of 
anti-B7-1. This limited analysis suggested that, following 
anti-B7-1 treatment in viva, T cells producing Th2 cyto- 
kines are induced, but these cytokines are not detected 
in the lymph node bulk cultures, possibly owing to the 
dominant inhibition by IFN'y. 
To address directly whether Th2 cells are preferentially 
generated following in viva administration of anti-B7-1 anti- 
body, we derived T cell clones from the PLP(139-151)- 
immunized, anti-B7-1-treated mice. A total of ten stable 
PLP(139-151)-specific lones were established from the 
anti-B7-1-treated mice, and the clones were classified by 
cytokine analysis as Thl (IFNy) or Th2 (IL-4 and IL-10) 
phenotypes. Table 2 summarizes the data on the cytokine 
Cell 
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Table 2. Cytokine Profile of PLP(139-151)-Specific T Cell Clones 




Clone IFN~, IL-4 IL-10 Subset 
Anti-B7-1 
1A8 0.04 5.00 0 Th2 
1 C2 0.20 5.00 0 Th2 
2F12 0.10 1.60 0 Th2 
1 F4 0.60 1.30 2.60 Th2 
2E10 0.30 1.60 0 Th2 
1 E3 0.04 >5 >5 Th2 
1 B3 0.50 0.50 0 Th2 
1 E6 0.00 0.20 >5 Th2 
2A2 2.20 0.10 0 Thl 
1A4 5.00 0.30 0 Thl 
Control immunoglobulin 
1 B7 5.40 0 0 Th 1 
1C3 1.00 0 0 Thl 
1C4 1.00 0 0 Thl 
1C7 >5 0 0 Thl 
1 D7 5.80 0 0 Thl 
1F7 3.20 0 0 Thl 
3F5 5.70 0 0 Thl 
4C3 2.10 0 0 Thl 
4F3 2.90 0 0 Thl 
4G3 3.10 0 0 Thl 
1 F7 2.70 0 0 Thl 
2C7 1.80 0 0 Thl 
4G2 2.70 0 0 Thl 
3E6 0.00 1.10 0 Th2 
3E5 0.00 1.25 0 Th2 
HEL ND 4.70 1. Th2 
Cytokine production by PLP(139-151)-specific T cell clones generated 
in the presence of anti-B7-1 antibody or control hamster IgG. T cell 
clones were derived from SJL mice immunized with PLP(139-151) 
and injected in vivo with anti-B7-1 antibody or control hamster IgG. T 
cell clones specific for the antigen derived from anti-B7-1-treated mice 
were tested for the production of IL-4, IL-10, and IFN'y. Data are pre- 
sented as the concentration of various cytokines produced by each 
individual clone. HEL is a hen-egg white lysozyme-specific T cell line. 
profile of these clones. Of the ten clones, seven produced 
IL-4 but not IFNy, and two of the clones produced IFNy 
but not IL-4. Of the ten clones, three produced IL-10. In 
summary, of the ten clones generated, two produced I FNy, 
one produced IL-10, five produced only IL-4, and two pro- 
duced both IL-4 and IL-10. None of the clones produced 
both IFNy and IL-4 and IL-10. In contrast, under the same 
culture conditions, T cell clones derived from SJL mice 
following immunization with PLP(139-151) in CFA and 
control IgG led to the generation of predominantly Thl  
cells (13 of 15) (Table 2). These data suggest that blocking 
the costimulatory molecule B7-1 in vivo by injection of anti- 
B7-1 antibody during induction of an immune response 
forces T cells into a Th2 pathway despite a microenviron- 
ment that strongly favors induction of Thl  cells. In vivo 
studies with two of the clones producing IL-4, IL-10, or 
both further suggest that these Th2 clones suppress clini- 
cal EAE when transferred into naive mice (see below). 
6 t Control Anti-lL4 ÷anti-BT-1 








Figure 5. Anti-lL-4 MAb Treatment Abrogates the Protective Effect of 
Anti-B7-1 Treatment In Vivo 
Three groups of four mice each were immunized with PLP(t39-151) 
in CFA (50 p.g/mouse) and injected as follows: group 1, Vl33 as control 
(10 mg) on day 0; group 2, 11 B11 anti-lL-4 MAb (10 rag) on day 0 plus 
1G 10 anti-B7-1 MAb (100 Ilg) every other day; group 3, anti-B7-1 MAb 
(100 p~g) every other day. 
ii: 
'i i .  
Anti-lL-4 MAb Treatment Abrogates the Protective 
Effect of Anti-B7-1 Treatment In Vivo 
It has been demonstrated that cytokines themselves can 
positively or negatively affect Th cell differentiation, as 
discussed earlier. It was possible, therefore, that antibod- 
ies to the B7-1 and B7-2 costimulatory molecules influence 
Th cell commitment by directly or indirectly causing cyto- 
kine release. Two approaches to explore this issue further, 
both using the in vivo EAE model, were taken. In the first 
approach, we asked whether preventing or neutralizing 
the secretion of I L-4 could abrograte the protective effect of 
the anti-B7-1 antibody on clinical disease. Mice immunized 
with PLP were, therefore, treated according to one of three 
protocols: a control group received control anti-VI33 anti- 
body; the second group received anti-B7-1 MAb at 100 
~g every other day, as described earlier; and a third group 
received the anti-BT-1 MAb plus a single dose of 10 mg 
of anti-lL-4 MAb on day 0. The mice were then monitored 
for clinical symptoms over 25 days. The results were clear 
cut. All control mice developed severe disease (average 
disease score at day 14 was 4.9), while anti-B7-1-treated 
mice, as before, developed much less severe disease 
(mean score at day 14 was 2.9). In contrast, mice given 
both anti-B7-1 and anti-lL-4 MAbs developed disease as 
severe as the mice in the control group (mean score at 
day 14 was 5.0) (Figure 5). We conclude that the protective 
effect of the anti-B7-1 MAb can be overcome by preventing 
or neutralizing the initial secretion of IL-4. 
Costimulators Affect Th Development and Autoimmunity 
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Figure 6. Adoptively Transferred Th2 Clones 
Protect Mice from Development of EAE and 
Abrogate Established Disease 
Groups of five mice each were immunized with 
PLP(139-151) in CFA and injected with 5 x 
106 Thl or Th2 clones at the time of immuniza- 
tion (A) or at the first signs of disease (B). 
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Immunizat ion  T cell clone 
PLP 139-151/CFA 
PLP 139-151/CFA 1E3 (Th2) 
PLP139-151/CFA 1A4 (Thl) 
PLP 139-151/CFA 1E6 (Th2) 
PEP 139-151/CFA HEL (Th2) tine 
Adoptive Transfer of PLP-Specific Th2 Clones 
Both Prevents EAE and Abrogates 
Established Disease 
In the second approach, we directly tested the effects of 
Th2 clones generated by blocking the B7-1 molecule in 
vivo on EAE. In this experiment, we transferred Th2 clones 
to mice at the same time that they were immunized for 
the development of EAE or at the first appearance of clini- 
cal signs of EAE. Clones transferred into mice (1A4, 1E3, 
and 1E6) were PLP(139-151) specific and were I-A s re- 
stricted, as determined by blocking with MAb 10.2.16 (data 
not shown). Th2 clones (1E3 and 1E6) transferred into 
mice on the day of immunization with PLP(139-151 )signif- 
icantly inhibited EAE. Mice injected with clone 1E3 (an 
IL-4 and IL-10 producer) showed little (mean score of 0.3) 
or no disease as compared with controls (Figure 6A, left 
and middle panels), whereas a Tht clone (1A4, an IFNy 
producer) that was transferred into mice increased the 
severity of disease above that of the controls, with a mean 
maximal score of 3 (Figure 6A, left panel). The transfer of 
a control Th2 line (H EL specific) did not ameliorate disease 
that was just as severe as in mice immunized with peptide 
alone, with a mean maximal score of 3 (Figure 6A, middle 
panel). When a second Th2 clone, 1E6, was introduced 
into mice again, no signs of disease at all were observed 
(Figure 6A, right panel). We conclude that transfer of Th2 
clones generated following treatment with anti-B7-1 MAb 
can prevent he induction of disease in an antigen-specific 
manner. 
To determine the possible therapeutic efficacy of this 
approach, we wished to determine whether established 
disease could be ameliorated or abrogated by Th2 clone 
transfer. Therefore, the Th2 clone 1E3 was transferred 
into mice after onset of initial signs of disease (limp tail 
or weight loss). This clone was injected on day 14, and 
the incidence of disease in the clone-injected group was 
40% compared with the controls (100%) (Figure 6B). In the 
clone-injected mice, the disease peaked (mean disease 
score of 0.6) on day 16-17, whereas in the control group, 
all the animals showed complete paralysis of fore and hind 
limbs (mean score of 4). These data suggest that an anti- 
gen-specific Th2 clone that produces IL-4, IL-10, or both 
is capable of treating mice that manifest clinical disease 
when introduced after the onset of disease. These data 
(Figures 5 and 6) taken together suggest that initial secre- 
tion of IL-4 by Th2 or CD4 ÷ NK1.1 ÷ cells may directly en- 
hance Th2 generation in an autocrine fashion and may 
also inhibit the generation of encephalitogenic Thl cells. 
Discussion 
We have examined the role of the costimulatory molecules 
B7-1 and B7-2 in the differentiation of Thp cells to mature 
Thl and Th2 effector cells and in the induction of an auto- 
immune disease, EAE. Utilizing MAbs specific for these 
two costimulatory molecules, we have shown that anti- 
B7-1 drives naive MBP-specific Thp cells along aTh2 path- 
way while anti-B7-2 favors Thl development. Administra- 
tion of anti-B7-1 antibody ameliorated an organ-specific 
autoimmune disease, EAE, whereas injection of anti-B7-2 
antibody significantly worsened clinical and histological 
disease. Blocking B7 molecules in vivo did not inhibit he 
generation of antigen-specific T cells, consistent with the 
in vitro differentiation results, but affected the cytokine 
profile of the responding T cells. Our results further sug- 
gest that the ability of anti-B7 antibodies to inhibit or en- 
hance EAE relates to the capacity of these antibodies dif- 
ferentially to activate Thl or Th2 cells/cytokines upon 
contact with Thp cells in the peripheral lymphoid compart- 
ment. Indeed, prevention of the initial secretion of IL-4 
abrogates the protective effect of anti-B7-1. In addition, 
we provide evidence that transfer of antigen-specific Th2 
Cell 
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clones generated by blocking the B7-1 molecule can pre- 
vent an organ-specific autoimmune disease and can abro- 
gate established disease. 
B7-Based Immunotherapy 
Interactions with costimulators expressed on APCs are 
required for T cell activation and cytokine secretion and 
in the prevention of tolerance (Harding et al., 1992; 
Lenschow et al., 1992). A number of studies have sug- 
gested that manipulating the interaction of B7 molecules 
with their counterreceptors on T cells provides effective 
immunotherapy in vivo. For example, a soluble CTLA-4 
immunoglobulin fusion protein prolonged allograft rejec- 
tion (Turka et al., 1992) and prevented xenograft rejection 
(Lenschow et al., 1992). Furthermore, CTLA-4 immuno- 
globulin inhibited antibody production (Linsley et al., 1992) 
and ameliorated murine lupus (Finck et al., 1994). Con- 
versely, we and others have recently demonstrated that 
provision of B7-1 to malignant umor cells results in their 
rejection and can reduce tumor burden and inhibit umor 
metastasis (Baskar et al., 1995; Townsend and Allison, 
1993; Chen et al., 1992) and that overexpression of B7-1 
in pancreatic islets results in autoimmune insulitis 
(Guarder et al., 1994). Here we have extended these appli- 
cations to include the treatment of an organ-specific auto- 
immune disease. 
EAE has been used as an experimental model of an 
autoimmune disease to study basic immune mechanisms 
and to develop immunotherapeutics to prevent or treat 
autoimmunity. A number of immunotherapeutic strategies 
have been successfully used in the treatment of EAE (re- 
viewed by Zamvil and Steinman, 1990). These include 
anti-MHC class II, anti-CD4, and specific anti-TCR V~ anti- 
bodies. These treatment strategies were aimed at blocking 
the generation of all Th cells or at least the specific T cells 
involved in the induction of EAE. In contrast, our approach 
was aimed at skewing the T cell response to a nonpatho- 
genic Th2 pathway. Both approaches inhibit he acute dis- 
ease; however, it is possible that they may have different 
effects on the incidence and intensity of relapsing disease 
(Jiang et al., 1992). Of particular interest is the observation 
that only anti-B7-1 and not anti-B7-2 inhibited EAE. In- 
deed, anti-B7-2 treatment worsened disease signs and 
increased the amount of CNS inflammation. If the B7-1 
costimulatory molecule is essential for the induction of 
encephalitogenic Thl cells, then its blockade would inhibit 
the generation of or induce anergy in these encephalito- 
genic T cells. This would also result in a compensatory 
increase of Th2 cells with the end result being an overall 
reduction in the production of Thl cytokines, including 
IFNy. However, this alone cannot account for the worsen- 
ing of EAE and increase in the production of Thl cells/ 
cytokines (IFN'y) by the administration of anti-B7-2 anti- 
body. An explanation might be provided by the temporal 
patterns of expression of these molecules during the de- 
velopment of a given immune response or by a preferential 
inhibition of IL-4 secretion by the anti-B7-2 MAb (see 
below). 
EAE Is Induced by Thl Cells, and Th2 Cells Can 
Prevent Induction of Disease and Abrogate 
Established Disease 
Myelin antigen (MBP or PLP)-reactive T cells that induce 
EAE have thus far all been shown to display a Thl pheno- 
type (Kuchroo et al., 1993; Baron et al., 1993). In addition, 
during progression of disease, Thl cyokines (IL-2, TNFI3, 
and IFN~,) are present in inflammatory EAE lesions, while 
Th2 cytokines are absent (Khoury et al., 1992), strongly 
suggesting that Thl cytokines play a role in the pathogene- 
sis of the disease. This is consistent with the presentdata, 
since mice immunized with PLP(139-151) and injected 
with either PBS or the control TR-310 antibody generate 
T cells that produced significant amounts of Thl (IL-2 and 
IFNT) but not detectable levels of Th2 (IL-4 and IL-10) cy- 
tokines. Administration of anti-B7-2 antibody significantly 
enhanced the severity of EAE, and this was accompanied 
by a marked increase in antigen-specific IFNy production 
by LNCs, suggesting that injection of anti-B7-2 antibody 
leads to the hyperinduction or activation of IFNT-producing 
Thl cells. On the other hand, administration of anti-B7-1 
antibody leads to amelioration of disease with a commen- 
surate decrease in the production of IFN~,, indicating that 
blocking the costimulatory B7-1 molecule in vivo inhibits 
(directly or indirectly) the generation of Thl cells/cyto- 
kines. Thus, our data indicate that anti-B7-1 and anti-B7-2 
antibodies have opposing effects in the induction of EAE 
and concurrently in the generation of Thl and Th2 cells/ 
cytokines. The presence of IL-4 alone in the brain in an 
asymptomatic treated animal, as well as our experiments 
with Th2 clones generated by the administration of anti- 
B7-1 antibody, further strengthens the argument that 
these cells/clones do not induce EAE on their own but 
can protect mice from the development of EAE. In other 
systems, regulatory T cells that suppress the development 
of EAE have also been shown to produce cytokines that 
correspond to the Th2 profile (Chen et al., 1994). Further- 
more, recovery from EAE in mice and rats is associated 
with an increase in the presence of Th2 cells and cytokines 
in the CNS (Khoury et al., 1992). The present findings 
demonstrate that an antigen-specific Th2 clone can pre- 
vent.the induction of an organ-specific autoimmune dis- 
ease and can abrogate established disease. These find- 
ings, together with the observation that administration of 
anti-B7-1 results in the preferential induction of antigen- 
specific Th2 cells, strongly suggests that the protective 
effects of anti-B7-1 antibody may be due to activation of 
the Th2 pathway and thus offer the basis for novel immuno- 
therapeutic strategies. Such strategies might rely on the 
manipulation of cytokines uch as IL-4, since blocking the 
initial production of IL-4 abrogated the protective ffect of 
the anti-B7-1 antibody. 
Role of the Costimulatory Molecules B7-1 
and B7-2 in Th Cell Differentiation 
Differentiation ofThp cells into Thl or Th2 ceils upon anti- 
genic stimulation in vivo has important biologic conse- 
quences. However, the processes that dictate whether an 




ILniY ~ @ IL-4 
[L-10 
Figure 7. Interaction of B7-1 and B7-2withtheSameCounterreceptor 
on a Thp Cell Results in Different Th Subset Generations 
immune response will be dominated by Thl  versus Th2 
cells are not well understood (Paul and Seder, 1994; Seder 
and Paul, 1994), although initial cytokine release, antigen 
concentration, and the route of antigen administration may 
all affect the outcome. The data presented here are direct 
evidence that interaction of the costimulatory molecules 
B7-1 or B7-2, with their counterreceptors CD28 and CTLA-4, 
on Thp cells during antigen presentation leads to polariza- 
tion of Th responses. The simplest interpretation of our 
data is that B7-1 preferentially acts as a costimulator for 
the generation of Thl  cells while B7-2 costimulates and 
induces Th2 cells (see model in Figure 7). Thus, blocking 
B7-1 will inhibit the generation of Thl  cells, while enhanc- 
ing the generation of Th2 cells and blocking B7-2 will have 
the opposite effect. If this hypothesis is correct, then the 
interaction of B7-1 and B7-2 molecules with their T cell 
counterreceptors likely generates different intracellular 
signals that lead to the differentiation of Thp cells along 
a Thl  or Th2 pathway. The recent evidence (Nun,s et al., 
1994) that triggering of CD28 with anti-CD28 antibody, but 
not with the ligand B7-1, can activate p21 r"  is intriguing 
in this regard. This raises the possibility that a differential 
effect on p21 ra" or other molecules implicated in CD28 
signaling (such as phosphatidyl inositol 3-kinase) (Prasad 
et al., 1994) would also be observed when interaction with 
B7-1 versus B7-2 ligands is compared. It is also possible 
that differential interaction of B7-1 and B7-2 with their two 
counterreceptors, CD28 and CTLA-4, may occur. Al- 
though several structural motifs are shared between the 
two amino acid sequences (Freeman et al., 1993a, 1993b; 
Azuma et al., 1993), binding studies have shown that the 
affinity of B7-1 for CTLA-4 is of 10- to 20-fold higher affinity 
than to CD28. Similar measurements have recently been 
published for B7-2 (Linsley et al., 1994), which demon- 
strate that the two costimulatory molecules do not bind 
equivalently to CTLA-4. Since CTLA-4 has recently been 
shown to function as a negative regulator of T cell activa- 
tion (Walunas et al., 1994), the more rapid dissociation of 
B7-2 from CTLA-4 could result in the effects observed. 
One outcome of this differential signaling could be the 
initial secretion of opposing cytokines that would drive Th 
lineage commitment. The observations that treatment with 
anti-lL-4 MAb abrogates the protective effect of anti-B7-1 
antibody together with the prevention of EAE by transfer 
of PLP-specific Th2 clones is consistent with a direct effect 
of costimulatory molecules on cytokine secretion. Alterna- 
tively, the polarization of Th cell responses by the addition 
of anti-B7 antibodies, observed in this study, may be an 
indirect effect of the antibodies themselves. A number of 
cell types, including T cells, macrophages, and dendritic 
cells, constitutively express B7-2 and can up-regulate ex- 
pression of B7-1 upon activation. Cross-linking costimula- 
tory molecules on the surface of these cells by antibody 
may lead to the production of specific cytokines and 
change the cytokine milieu in the microenvironment, 
thereby polarizing Th cell responses. If the latter hypothe- 
sis is correct, then cross-linking B7-1 versus B7-2 would 
lead to the production of different cytokines, such as IL-12, 
that may promote or inhibit generation of Thl  versus Th2 
cells. The identification of intracellular signals that are gen- 
erated by interaction of B7-1 and B7-2 with the same coun- 
terreceptors (CD28 and CTLA-4) on a Thp cell may provide 
insight into the molecular mechanisms responsible for Th 
cell differentiation, allowing selective manipulation of the 
immune response in disease. 
Experimental Procedures 
Mice 
Female SJI./J mice 4 to 8 weeks of age (Jackson Laboratory, Bar 
Harbor, ME) were maintained in accordance with the guidelines of 
the Committee on Animals of the Harvard Medical School and the 
Committee on Care and Use of Laboratory Animals of the Institute of 
Laboratory Animal Resources, National Research Council, as stated 
in Department of Health and Human Services publication 85-23 (re- 
vised in 1985). 
Transgenic B10.PL mice expressing TCRs for MBP have been de- 
scribed previously (Goverman et al., 1993) and express Va2.3- and 
VI38.2-containing TCR genes from a B10.PL-derived T cell hybrid spe- 
cific for MBP Ac(1-11). Separate TCR ~ and ~ chain transgenic lines 
were established and the lines bred together to generate mice express- 
ing a complete transgenic TCR. Expression of transgenes was evalu- 
ated by genotyping tail DNA and by flow cytometry of peripheral blood 
T cells utilizing MAbs specific for TCR Va2 and V~8.2 regions. An 
additional MBP TCR transgenic line expressing V~4 and V1~8.2 that 
recognizes MBP Ac(1-17) was also utilized (Lafaille et al., 1994) (gift 
of Dr. C. Janeway, Yale University, New Haven, CT). 
Antigens 
PLP(139-151) (HSLGKWLGHPDKF), PLP(190-209) (SKTSASIGSL- 
CADARMYYGVL), and MBP Ac(1-11) (AcASQKRPSQRHG) peptides 
were prepared according to published sequences (Laursen et al., 
1984; Newman et al., 1987) except that serine was always substituted 
for cysteine at position 140 in the peptide PLP(139-151) (luohy et al., 
1989). Peptides were synthesized in the laboratory of Dr. R. Laursen 
(Department of Chemistry, Boston University, Boston, MA) on a Milli- 
gen model 9050 synthesizer using Fmoc chemistry or by H. Freisheim 
(Medical College of Ohio, Toledo, OH) on an Applied Biosystems model 
430A synthesizer using Milligen PAL resins or RINK amide resins. 
Antibodies 
Anti-B7-1 (1G10) and anti-B7-2 (2D10) have been described previously 
(Nabavi et al., 1992; Chen et al., 1994) and were derived from the 
same somatic cell fusion. The MAbs were purified from ascitic fluid 
on protein G columns. The anti-B7-1 and B7-2 antibodies are of the 
IgG2a and IgG2b isotypes, respectively. A second anti-B7-2 antibody 
(GL-1) of rat IgG2a isotype was obtained from ATCC. Hybridoma cells 
were grown as ascites and purified over a protein G column. Purified 
rat IgG2a and IgG2b antibodies (Pharmingen, San Diego, CA) were 
used as isotype controls. A rat anti-Vlt,7 (TR-310) antibody (rat IgG2a) 
was purified from ascitic fluid on a protein G column and used as an 
additional control. The rat MAb to mouse IL-4 was the gift of Dr. W. E. 
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Paul (National Institutes of Health, Bethesda, MD), and the anti-V~3 
antibody KJ25a, used as a control, was the gift of Dr. J. Kappler (Na- 
tional Jewish Hospital and Research Center, Denver, CO). 
Induction of EAE 
SJL mice were injected subcutaneously in the flank with 25-100 ~g 
of peptide PLP(139-151) and 400 p_g of Mycobacterium tuberculosis 
H37Ra (Difco Laboratories, Detroit, MI) in an emulsion consisting of 
equal volumes of PBS and CFA. Each mouse was also injected intrave- 
nously on day 0 and day 2 or 3 with 10 ~ heat-killed Bordetella pertussis 
bacilli (Massachusetts Public Health Biological Laboratories, Boston, 
MA). To test the efficacy of the antibodies in the induction and inhibition 
of EAE in vivo, we injected mice with anti-B7 or control antibodies (100 
p.g/mouse) intraperitoneally every other day following immunization, 
according to various protocols as described in Results. 
Clinical assessment was carried out daily according to the following 
criteria: 0, no disease; 1, decreased tail tone or slightly clumsy gait; 
2, tail atony, moderately clumsy gait, poor righting ability, or some 
combination of these symptoms; 3, limb weakness; 4, limb paralysis; 
5, moribund state. Animals were sacrificed at the termination of the 
experiment or at the peak of the disease. Mice that showed no clinical 
signs were sacrificed at the conclusion of the experiment. Brains and 
spinal cords were removed and fixed in 10% formalin, and paraffin- 
embedded sections were stained with Luxol fast blue-hematoxylin 
and eosin for light microscopy. Histological disease was quantified by 
counting inflammatory loci in meninges and parenchyma (Sobel et al., 
1989). 
In Vitro Proliferative Response and Cytokine Production 
of Antigen-Primed LNCs 
Groups of mice immunized subcutaneously with peptide PLP(139-151) 
in CFA for the induction of EAE were sacrificed at various timepoints 
during the course of disease. Inguinal, prescapular, and para-aortic 
lymph nodes were removed and dissociated in Dulbecco's minimum 
essential medium (DMEM). LNCs from these mice were used for in 
vitro proliferative assays and production of cytokines following in vitro 
stimulation. 
Proliferative Assays 
For in vitro proliferation, LNCs were cultured for 72 hr in flat-bottomed 
96-well plates in the presence of various concentrations of peptide 
and then pulsed with 1 p, Ci of [3H]thymidine for the last 16-18 hr of 
incubation, and mean thymidine incorporation in triplicate wells was 
calculated. The data of the proliferative assays are presented as stimu- 
lation indices for easy comparison of the proliferative responses: mean 
cycles per minute in the test wells divided by mean counts per minute 
in the control wells (with medium). 
Cytokine ELISA 
The amount of cytokines produced by LNCs was determined by ELISA. 
LNCs obtained from mice immunized with PLP(139-151) in CFA and 
injected with the various antibodies were activated with PLP(139-151) 
control peptide in vitro, and culture supernatants were collected from 
separate wells on day 1 and day 2. In brief, 96-well plates were coated 
overnight with primary anti-cytokine capture antibody (1 p.g/ml) specific 
for a particular cytokine. The plates were washed twice and, after a 
2 hr incubation with PBS plus 15% blocking reagent (Kirkegaard and 
Perry Laboratories, Gaithersburg, MD), the supernatants from the acti- 
vated clones and the standards were added. After overnight incubation 
at 4°C, the plates were washed, and diluted biotinylated anti-cytokine- 
detecting MAb (1 p.g/ml) was added and incubated at room tempera- 
ture for 1 hr. The plates were washed and further developed by adding 
avidin-peroxidase and its substrate, and absorbance was measured 
on a 450 nm wavelength spectrophotometer. The amount of cytokine 
in each supernatant was extrapolated from the standard curve. The 
antibody pairs used were as follows, listed by capture/biotinylated de- 
tection: IL-2, JES6-1A12/JE5H4; I L-4, BVD4-1 D11/BVD6-24G2; IL-10, 
JES5-2A5/SXC-1; IFNy, R4-6A2/XMG1.2 (all from Pharmingen, San 
Diego, CA). The standards were recombinant cytokine curves gener- 
ated in 1:2 dilutions from 39 to 2500 pg/ml for IL-2, IL-4, and IL-10 
and from 78 to 5000 pg/ml for IFNy with detectable readings at the 
lowest dilutions. 
In Vitro Differentiation and Phenotype of Transgenic T Cells 
Spleen cells (5 x 106/ml) obtained from a naive MBP TCR transgenic 
mouse (Goverman et al., 1993) were equally divided into four aliquots 
and cultured in a 24-well plate with one of the following antibody re- 
agents at 20 ~g/ml: anti-B7-1 (1G10), anti-B7-2 (2D10), purified rat 
immunoglobulin, or PBS, with or without addition of the antigen MBP 
Ac(1-11) (10 I~g/ml). Culture supernatants were harvested 2 days after 
activation and tested for cytokine production by ELISA. The cultures 
were further propagated for an additional 21 days by addition of media 
containing 5% human IL-2. The live T cells were purified, resuspended 
at 5 x 108 cells/ml, and activated in the presence ofthe corresponding 
antibody reagent and syngeneic spleen cells, such as APCs (10qml), 
with or without addition of MBP Ac(1-11) (10 ~g/ml). The culture super- 
natants were harvested 48 hr after activation, and cytokine content 
was determined by ELISA. 
Derivation and Maintenance of T Cell Clones 
SJL mice were injected subcutaneously in each flank with 100 I~g of 
PLP(139-151) in CFA plus 400 p.g of M. tuberculosis H37RA and then 
injected with anti-BT-1 antibody (100 I~g intravenously on days 0 and 
2) (Razi-Wolf et el., 1992) or control hamster IgG (Cappel, Durham, 
NC). LNCs were removed from mice 10 days after immunization and 
cultured for 5 days with PLP(139-151) peptide (20 ~g/ml) in DMEM 
containing 1% autologous erum. Live cells were isolated on a Ficoll- 
Hypaque gradient and grown in 5% 11_-2 medium (T-STIM, Collabora- 
tive Biomedical Products, Bedford, MA) for 14 days. The cells were 
activated once again in the presence of PLP(139-151) and SJL spleen 
cells as APCs, The T cells were cloned by limiting dilution 3 days after 
the last activation and individual T cell clones expanded to obtain 
sufficient numbers. The cloned cells were activated with PLP(139- 
151), and the cytokine profile of each T cell clone was established by 
cytokine ELISAs. 
Adoptive Transfer of Clones 
T cell clones were activated with APCs and peptide PLP(139-151) (20 
~g/ml) for 3 days, after which live cells were isolated by FicolI-Hypaque 
density gradient centrifugation. Clones (Thl or Th2; 5 x 106/mouse) 
were injected intravenously into mice that were injected subcutane- 
ously with 50 p,g of PLP(139-151) in CFA at the time of transfer. A 
control line secreting IL-4 and IL-10 specific for hen-egg white lyso- 
zyme (HEL) was also transferred into PLP peptide-immunized mice. 
A Th2 clone (1E3, producing IL-4 and IL-10) was also transferred into 
mice after the first sign of disease (limp tail). The disease course was 
followed for 25-30 days. 
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